Increased Serum Leptin Level Predicts Bone Mineral Density in Hemodialysis Patients
Table 2
Clinical characteristics with gender, comorbidity, drugs used, and lumbar bone mineral density levels among hemodialysis patients.
Characteristic
Number (%)
Lumbar BMD (g/cm2)
value
Gender
Male
48 (49.0)
1.03 ± 0.16
<0.001
Female
50 (51.0)
0.84 ± 0.17
Diabetes
No
51 (52.0)
0.89 ± 0.20
0.052
Yes
47 (48.0)
0.97 ± 0.18
Hypertension
No
49 (50.0)
0.91 ± 0.19
0.210
Yes
49 (50.0)
0.96 ± 0.19
Hyperlipidemia
No
73 (74.5)
0.92 ± 0.19
0.306
Yes
25 (25.5)
0.96 ± 0.20
ACE inhibitor or ARB use
No
77 (78.6)
0.94 ± 0.19
0.579
Yes
21 (21.4)
0.91 ± 0.20
β-Blocker use
No
66 (67.3)
0.94 ± 0.21
0.747
Yes
32 (32.7)
0.92 ± 0.16
CCB use
No
64 (65.3)
0.94 ± 0.20
0.657
Yes
34 (34.7)
0.92 ± 0.17
Statin use
No
82 (83.7)
0.92 ± 0.19
0.368
Yes
16 (16.3)
0.97 ± 0.20
Fibrate use
No
89 (90.8)
0.93 ± 0.19
0.696
Yes
9 (9.2)
0.95 ± 0.22
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker. was considered statistically significant. Data are expressed as means ± standard deviation and test by Student’s t-test.
